New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
11:21 EDTMMM, SMI, PEG, MRO, KGC, ISIS, HRZN, FLT, ETP, CXO, OZRK, ATK, SBUXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3M Company (MMM) upgraded to Neutral from Reduce at Nomura... Alliant Techsystems (ATK) upgraded to Buy from Neutral at Goldman... Bank of the Ozarks (OZRK) upgraded to Buy from Neutral at Sterne Agee... Concho Resources (CXO) upgraded to Buy from Hold at Stifel Nicolaus... Energy Transfer Partners (ETP) upgraded to Equal Weight at Morgan Stanley... FleetCor (FLT) upgraded to Buy from Neutral at Citigroup... Horizon Technology (HRZN) upgraded to Buy from Hold at Gilford Securities... Isis Pharmaceuticals (ISIS) upgraded to Outperform from Neutral at Cowen... Kinross Gold (KGC) upgraded to Outperform from Neutral at Macquarie... Marathon Oil (MRO) upgraded to Overweight from Neutral at JPMorgan.... PSEG (PEG) upgraded to Hold from Sell at ISI Group... Semiconductor Manufacturing (SMI) upgraded to Market Perform at Bernstein... Starbucks (SBUX) upgraded to Buy from Hold at Argus.
News For MMM;ATK;OZRK;CXO;ETP;FLT;HRZN;ISIS;KGC;MRO;PEG;SMI;SBUX From The Last 14 Days
Check below for free stories on MMM;ATK;OZRK;CXO;ETP;FLT;HRZN;ISIS;KGC;MRO;PEG;SMI;SBUX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2014
09:12 EDTPEGPSEG acquires solar facility in Vermont from juwi solar
PSEG will acquire the ERWR Whitcomb Farm Solar project from juwi solar. The facility has a 25-year power purchase agreement with Vermont Electric Power Producers as part of the Vermont Sustainably Priced Energy Enterprise Development program. The acquisition will increase PSEG's Solar Source portfolio to 110 MWdc.
06:48 EDTSBUXFive people detained regarding China meat scandal investigation, Reuters says
Subscribe for More Information
July 22, 2014
18:02 EDTSBUXStarbucks plans 260 store openings in Japan, Nikkei says
Subscribe for More Information
13:10 EDTMMM3M Company July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
12:53 EDTSMIApplied Materials drops following report of opposition to merger
Subscribe for More Information
06:43 EDTSBUXChina food scandal expands, ropes-in Starbucks, others, Reuters says
Subscribe for More Information
July 21, 2014
12:17 EDTSBUXStarbucks July weekly volatility elevated into Q3 and outlook
Subscribe for More Information
11:00 EDTSBUXStarbucks China says one of its suppliers got meat from Husi, Bloomberg reports
Subscribe for More Information
08:35 EDTATKATK receives international contracts totaling $220M from U.S. allies
Subscribe for More Information
July 20, 2014
20:18 EDTSMISemiconductor Manufacturing raises Q2 gross margin view to 27%-29% from 22%-24%
Subscribe for More Information
July 18, 2014
09:48 EDTKGCActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NQ GOOG GOOGL TSLA KGC TWTR AMZN ELNK AMGN FB
06:37 EDTSBUXStarbucks to test mobile phone ordering, Re/code reports
Subscribe for More Information
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
17:06 EDTFLTFleetCor initiated with a Neutral at Piper Jaffray
Subscribe for More Information
10:35 EDTETPOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTPEGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTATKATK and Alenia Aermacchi complete testing on Italian Air Force aircraft
Subscribe for More Information
07:45 EDTPEGPSEG upgraded to Buy from Hold at Argus
Argus upgraded PSEG to Buy from Hold due to an improved outlook for forward power prices, valuation, and an expanding infrastructure improvement program. Price target is $44.
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
05:33 EDTMMM3M to acquire Sumitomo Electric interest in Sumitomo 3M for $885M
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use